SCHEMBL5033034

SCHEMBL5033034

CC(C)(C)OC(=O)CC[C@@H](C(=O)O)N(CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
NOD1 Q9Y239 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3844876 0.93 EPOR (0.33) MEN1GAAKMT2A
SCHEMBL3841443 0.93 TDP1 (0.39) MEN1GAAKMT2A
SCHEMBL3498361 0.86 TDP1 (0.33)
SCHEMBL7881945 0.84 CPB2 (0.36) MEN1GAAKMT2A
SCHEMBL14345486 0.83 TDP1 (0.31) MEN1GAAKMT2A
SCHEMBL5032518 0.83 TDP1 (0.31) MEN1GAAKMT2A
SCHEMBL4564930 0.83 TDP1 (0.31) MEN1GAAKMT2A
SCHEMBL8388793 0.80 KDM4E (0.32) MEN1GAAKMT2A
SCHEMBL12694735 0.80 TDP1 (0.33)
SCHEMBL3498662 0.80 MEN1 (0.30) MEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1935435-B1 Blood pool agents for nuclear magnetic resonance diagnostics BRACCO IMAGING SPA (IT) 2017-09-06 EP disclosed
EP-1935435-A2 Blood pool agents for nuclear magnetic resonance diagnostics Bracco Imaging S.p.A (IT) 2008-06-25 EP disclosed
EP-1259532-B1 BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF BRACCO IMAGING SPA (IT) 2005-05-04 EP disclosed
US-6803030-B2 CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING BRACCO IMAGING S.P.A. (IT) 2004-10-12 US disclosed
US-20030113265-A1 Bile acids conjugates with metal ion chelates and the use thereof BRACCO IMAGING S.P.A. (IT) 2003-06-19 US disclosed
EP-1259532-A1 BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF Bracco Imaging S.p.A. (IT) 2002-11-27 EP disclosed
US-6461588-B1 VASCULAR SYSTEMS BRACCO IMAGING S.P.A. (IT) 2002-10-08 US disclosed
WO-2001064708-A1 BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF BRACCO IMAGING S.P.A. (IT) 2001-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030113265-A1 Bile acids conjugates with metal ion chelates and the use thereof SLC10A2, SLC10A1, NR1H4 MEN1 168/4885GAA 984/4885KMT2A 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.